DOACs vs Warfarin for Post-myocardial Infarction Left Ventricular Thrombus: A GRADE-assessed Meta-Analysis With Trial Sequential Analysis of Randomized Trials

Ahmed Elbataa, Ameer Awashra, Ahmed Elazab, Noha Hammad, Ahmed Mansour, Amro Ali, Mohamed Yasser Elnaggar, Elsayed Balbaa, Abdalhakim Shubietah, Mohamed S. Elgendy, Mohammed A. Elbahloul, Fawzi Zghyer, Mohammed Al-Sadawi, Amr Salama, Faculty of Medicine, Al-Azhar University, Department of Medicine, An Najah National University, Faculty of Medicine, South Valley University, Faculty of Medicine, Port-Said University, Department of Medicine, Community Regional Medical Center, Faculty of Medicine, Mansoura University, Faculty of Medicine, Alexandria University, Department of Medicine, Advocate Illinois Masonic Medical Center, Faculty of Medicine, Tanta University, Faculty of Medicine, Kafr El Sheik University, Kafr El Sheikh, Department of Cardiovascular Medicine, Vascular and Thoracic Institute, Cleveland Clinic, Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham

Clinical and Applied Thrombosis/Hemostasis

Published online on July 13, 2026

Abstract

Clinical and Applied Thrombosis/Hemostasis, Volume 32, January-December 2026.
Background and PurposeCurrent AHA and ACC guidelines warrant studies comparing direct oral anticoagulant (DOAC) and warfarin for post-myocardial infarction (MI) left ventricular thrombus (LVT). DOAC is increasingly considered due to its minimal monitoring ...